Product innovation and the development of high-qualitative assays are the need of the hour
LONDON, Sept. 4, 2013 /PRNewswire/ — Rapid growth in microRNA (miRNA) research over the past two years, owing to its diagnostic and therapeutic potential, has fueled development in the global miRNA tools and services market. Of the various miRNA technologies, which include quantitative real-time polymerase chain reaction (qRT PCR), microarrays and functional tools, qRT PCR remains the fastest-growing, while microarray is gradually being replaced by next-generation sequencing platforms.
New analysis from Frost & Sullivan (http://www.frost.com/prod/servlet/svcg.pag/HCLS), Global Analysis of MicroRNA Tools and Services Market, finds that the tools side of the market earned revenues of $110.0 million in 2012 and estimates this to more than double to reach $247.7 million in 2017. The US contributed to about 47% of the revenue followed by 36.7% from Europe, while leaving the rest to APAC and ROW. The miRNA services market earned revenues of $35.1 million in 2012 and this is expected to grow to $63.3 million in 2017. The end users covered are academic and research institutes, core facilities, and pharmaceutical and biotech companies.
The growth of therapeutic and diagnostic enterprises, higher research funding and increased outsourcing to contract research organizations in the US will present immense opportunities for the miRNA tools and services market. At the same time, [click to continue…]
Life Technologies has 2 TaqMan® qPCR consumables grants available for European research teams*. You have the opportunity to make your project come to life with a grant of either 10,000 or 5,000 euros*.
To apply for the grant you will need to tell Life Technologies about a specific challenge you would like to tackle, what you aim to achieve and outline your motivation for pursuing your study.
Applications will be accepted for a very limited time. Pre-registration is open now. If you would like to pre-register for the TaqMan® Grant please visit www.taqmangrant.com
*Please see Terms and Conditions, available on the TaqMan® Grant website for country eligibility and further details.
Incoming search terms for this article:
RNA expression analysis can be acomplished by microarrays, next-gen sequencing, in situ hybridization or qRT-PCR, but not all investigators have these capabilities in their own labs. Whether constrained by space, infrastructure, know-how, or time, many have no choice but to outsource these types of analyses to others. Often, that means employing a university core facility. But some elect to go off campus altogether, enlisting commercial service providers instead. Here are some accounts of outsourcing experiences by a few RNA researchers. (read more… )
Heart disease and cancer represent the number one and number two killer diseases in developed countries. Identifying biomarkers to detect these and other diseases at early stages remains an important research goal and researchers are scrambling for ways to identify contributing factors to the pathogenesis of diseased cells in the body. In recent years, research has turned to the study of microRNA (miRNA) as possible biomarkers due to their extensive role in biological processes and cell functionality in normal vs. diseased cells. Microarrays combined with quantitative real-time PCR (qRT-PCR) validation are proving to be valuable tools for miRNA expression profiling and are predicted to play a crucial role in biomarker discovery and detection. [click to continue…]